
Biologics
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News

At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

Acceptance is greater in oncology than in other specialties.

Challenges with biosimilars and unbranded biologics are discussed and how can they be improved.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Weakened brain connections linked to cognitive deficits in schizophrenia
3
What UnitedHealth Groupโs earnings call reveals about managed care trends
4
Could GLP-1s help with cognitive symptoms, pychosis of schizophrenia?
5






























